Dynamical Network Biomarkers Research Articles

Mathematical modeling and computational prediction of cancer drug resistance.

Diverse forms of resistance to anticancer drugs can lead to the failure of chemotherapy. Drug resistance is one of the most intractable issues for successfully treating cancer in current clinical practice. Effective clinical approaches that could counter drug resistance by restoring the sensitivity of tumors to the targeted agents are urgently needed. As numerous experimental results on resistance mechanisms have been obtained and a mass of high-throughput data has been accumulated, mathematical modeling and computational predictions using systematic and quantitative approaches have become increasingly important, as they can potentially provide deeper insights into resistance mechanisms, generate novel hypotheses or suggest promising treatment strategies for future testing. In this review, we first briefly summarize the current progress of experimentally revealed resistance mechanisms of targeted therapy, including genetic mechanisms, epigenetic mechanisms, posttranslational mechanisms, cellular mechanisms, microenvironmental mechanisms and pharmacokinetic mechanisms. Subsequently, we list several currently available databases and Web-based tools related to drug sensitivity and resistance. Then, we focus primarily on introducing some state-of-the-art computational methods used in drug resistance studies, including mechanism-based mathematical modeling approaches (e.g. molecular dynamics simulation, kinetic model of molecular networks, ordinary differential equation model of cellular dynamics, stochastic model, partial differential equation model, agent-based model, pharmacokinetic–pharmacodynamic model, etc.) and data-driven prediction methods (e.g. omics data-based conventional screening approach for node biomarkers, static network approach for edge biomarkers and module biomarkers, dynamic network approach for dynamic network biomarkers and dynamic module network biomarkers, etc.). Finally, we discuss several further questions and future directions for the use of computational methods for studying drug resistance, including inferring drug-induced signaling networks, multiscale modeling, drug combinations and precision medicine.

Sparse Pathway-Induced Dynamic Network Biomarker Discovery for Early Warning Signal Detection in Complex Diseases.

In many complex diseases, the transition process from the healthy stage to the catastrophic stage does not occur gradually. Recent studies indicate that the initiation and progression of such diseases are comprised of three steps including healthy stage, pre-disease stage, and disease stage. It has been demonstrated that a certain set of trajectories can be observed in the genetic signatures at the molecular level, which might be used to detect the pre-disease stage and to take necessary medical interventions. In this paper, we propose two optimization-based algorithms for extracting the dynamic network biomarkers responsible for catastrophic transition into the disease stage, and to open new horizons to reverse the disease progression at an early stage through pinpointing molecular signatures provided by high-throughput microarray data. The first algorithm relies on meta-heuristic intelligent search to characterize dynamic network biomarkers represented as a complete graph. The second algorithm induces sparsity on the adjacency matrix of the genes by taking into account the biological signaling and metabolic pathways, since not all the genes in the ineractome are biologically linked. Comprehensive numerical and meta-analytical experiments verify the effectiveness of the results of the proposed approaches in terms of network size, biological meaningfulness, and verifiability.

Detecting early-warning signals for influenza A pandemic based on protein dynamical network biomarkers.

The outbreak of influenza A comes from a relatively stable state is a critical phenomenon on epidemic. In this paper, influenza A varying from different states is studied in the method of dynamical network biomarkers (DNB). Through studying DNB of influenza A virus protein, we can detect the warning signals of outbreak for influenza A and obtain a composite index. The composite index varies along with the state of pandemic influenza, which gives a clue showing the turn point of outbreak. The low value (<1) steady state of the composite index means influenza A is normally in the relatively steady stage. Meanwhile, if the composite index of a certain year increases by more than 0.8 relative to the previous year and it is less than 1 and it increases sharply and reaches a peak being larger than 1 in next year, it means the year is normal in the critical state before outbreak and the next year is normally in the outbreak state. Therefore, we can predict the outbreak of influenza A and identify the critical state before influenza A outbreak or outbreak state by observing the variation of index value.

Several Indicators of Critical Transitions for Complex Diseases Based on Stochastic Analysis.

Many complex diseases (chronic disease onset, development and differentiation, self-assembly, etc.) are reminiscent of phase transitions in a dynamical system: quantitative changes accumulate largely unnoticed until a critical threshold is reached, which causes abrupt qualitative changes of the system. Understanding such nonlinear behaviors is critical to dissect the multiple genetic/environmental factors that together shape the genetic and physiological landscape underlying basic biological functions and to identify the key driving molecules. Based on stochastic differential equation (SDE) model, we theoretically derive three statistical indicators, that is, coefficient of variation (CV), transformed Pearson's correlation coefficient (TPC), and transformed probability distribution (TPD), to identify critical transitions and detect the early-warning signals of the phase transition in complex diseases. To verify the effectiveness of these early-warning indexes, we use high-throughput data for three complex diseases, including influenza caused by either H3N2 or H1N1 and acute lung injury, to extract the dynamical network biomarkers (DNBs) responsible for catastrophic transition into the disease state from predisease state. The numerical results indicate that the derived indicators provide a data-based quantitative analysis for early-warning signals for critical transitions in complex diseases or other dynamical systems.

Single-Cell-Based Analysis Highlights a Surge in Cell-to-Cell Molecular Variability Preceding Irreversible Commitment in a Differentiation Process.

In some recent studies, a view emerged that stochastic dynamics governing the switching of cells from one differentiation state to another could be characterized by a peak in gene expression variability at the point of fate commitment. We have tested this hypothesis at the single-cell level by analyzing primary chicken erythroid progenitors through their differentiation process and measuring the expression of selected genes at six sequential time-points after induction of differentiation. In contrast to population-based expression data, single-cell gene expression data revealed a high cell-to-cell variability, which was masked by averaging. We were able to show that the correlation network was a very dynamical entity and that a subgroup of genes tend to follow the predictions from the dynamical network biomarker (DNB) theory. In addition, we also identified a small group of functionally related genes encoding proteins involved in sterol synthesis that could act as the initial drivers of the differentiation. In order to assess quantitatively the cell-to-cell variability in gene expression and its evolution in time, we used Shannon entropy as a measure of the heterogeneity. Entropy values showed a significant increase in the first 8 h of the differentiation process, reaching a peak between 8 and 24 h, before decreasing to significantly lower values. Moreover, we observed that the previous point of maximum entropy precedes two paramount key points: an irreversible commitment to differentiation between 24 and 48 h followed by a significant increase in cell size variability at 48 h. In conclusion, when analyzed at the single cell level, the differentiation process looks very different from its classical population average view. New observables (like entropy) can be computed, the behavior of which is fully compatible with the idea that differentiation is not a “simple” program that all cells execute identically but results from the dynamical behavior of the underlying molecular network.

Discovering a critical transition state from nonalcoholic hepatosteatosis to nonalcoholic steatohepatitis by lipidomics and dynamical network biomarkers.

Nonalcoholic fatty liver disease (NAFLD) is a major risk factor for type 2 diabetes and metabolic syndrome. However, accurately differentiating nonalcoholic steatohepatitis (NASH) from hepatosteatosis remains a clinical challenge. We identified a critical transition stage (termed pre-NASH) during the progression from hepatosteatosis to NASH in a mouse model of high fat-induced NAFLD, using lipidomics and a mathematical model termed dynamic network biomarkers (DNB). Different from the conventional biomarker approach based on the abundance of molecular expressions, the DNB model exploits collective fluctuations and correlations of different metabolites at a network level. We found that the correlations between the blood and liver lipid species drastically decreased after the transition from steatosis to NASH, which may account for the current difficulty in differentiating NASH from steatosis based on blood lipids. Furthermore, most DNB members in the blood circulation, especially for triacylglycerol (TAG), are also identified in the liver during the disease progression, suggesting a potential clinical application of DNB to diagnose NASH based on blood lipids. We further identified metabolic pathways responsible for this transition. Our study suggests that the transition from steatosis to NASH is not smooth and the existence of pre-NASH may be partially responsible for the current clinical limitations to diagnose NASH. If validated in humans, our study will open a new avenue to reliably diagnose pre-NASH and achieve early intervention of NAFLD.

Editorial: Protein Interaction Networks in Health and Disease.

Editorial: Protein Interaction Networks in Health and Disease.

Complex network-based approaches to biomarker discovery.

Many studies on biomarker discovery have been done by analyzing mutations in DNA sequences and differences in gene expression patterns. As a new branch of the latter approach, the concept of network biomarkers has been proposed, in which expression data of small subnetworks are used as markers. Furthermore, network biomarkers have been extended to dynamical network biomarkers, in which time series expression data of subnetworks are used as markers. On the other hand, the methodologies in complex networks have also been applied to biomarker discovery. For example, various centrality measures and the concept of observability have been applied. In this article, we review these new approaches for biomarker discovery with focusing on the computational/methodological aspects.

Using Multi-objective Optimization to Identify Dynamical Network Biomarkers as Early-warning Signals of Complex Diseases.

Biomarkers have gained immense scientific interest and clinical value in the practice of medicine. With unprecedented advances in high-throughput technologies, research interest in identifying novel and customized disease biomarkers for early detection, diagnosis, or drug responses is rapidly growing. Biomarkers can be identified in different levels of molecular biomarkers, networks biomarkers and dynamical network biomarkers (DNBs). The latter is a recently developed concept which relies on the idea that a cell is a complex system whose behavior is emerged from interplay of various molecules, and this network of molecules dynamically changes over time. A DNB can serve as an early-warning signal of disease progression, or as a leading network that drives the system into the disease state, and thus unravels mechanisms of disease initiation and progression. It is therefore of great importance to identify DNBs efficiently and reliably. In this work, the problem of DNB identification is defined as a multi-objective optimization problem, and a framework to identify DNBs out of time-course high-throughput data is proposed. Temporal gene expression data of a lung injury with carbonyl chloride inhalation exposure has been used as a case study, and the functional role of the discovered biomarker in the pathogenesis of lung injury has been thoroughly analyzed.

Detection of Predisease States by Dynamical Network Biomarkers

Detection of Predisease States by Dynamical Network Biomarkers

Identifying critical differentiation state of MCF-7 cells for breast cancer by dynamical network biomarkers.

Identifying the pre-transition state just before a critical transition during a complex biological process is a challenging task, because the state of the system may show neither apparent changes nor clear phenomena before this critical transition during the biological process. By exploring rich correlation information provided by high-throughput data, the dynamical network biomarker (DNB) can identify the pre-transition state. In this work, we apply DNB to detect an early-warning signal of breast cancer on the basis of gene expression data of MCF-7 cell differentiation. We find a number of the related modules and pathways in the samples, which can be used not only as the biomarkers of cancer cells but also as the drug targets. Both functional and pathway enrichment analyses validate the results.

Deciphering deterioration mechanisms of complex diseases based on the construction of dynamic networks and systems analysis.

The early diagnosis and investigation of the pathogenic mechanisms of complex diseases are the most challenging problems in the fields of biology and medicine. Network-based systems biology is an important technique for the study of complex diseases. The present study constructed dynamic protein-protein interaction (PPI) networks to identify dynamical network biomarkers (DNBs) and analyze the underlying mechanisms of complex diseases from a systems level. We developed a model-based framework for the construction of a series of time-sequenced networks by integrating high-throughput gene expression data into PPI data. By combining the dynamic networks and molecular modules, we identified significant DNBs for four complex diseases, including influenza caused by either H3N2 or H1N1, acute lung injury and type 2 diabetes mellitus, which can serve as warning signals for disease deterioration. Function and pathway analyses revealed that the identified DNBs were significantly enriched during key events in early disease development. Correlation and information flow analyses revealed that DNBs effectively discriminated between different disease processes and that dysfunctional regulation and disproportional information flow may contribute to the increased disease severity. This study provides a general paradigm for revealing the deterioration mechanisms of complex diseases and offers new insights into their early diagnoses.

Pathway mapping and development of disease-specific biomarkers: protein-based network biomarkers.

It is known that a disease is rarely a consequence of an abnormality of a single gene, but reflects the interactions of various processes in a complex network. Annotated molecular networks offer new opportunities to understand diseases within a systems biology framework and provide an excellent substrate for network-based identification of biomarkers. The network biomarkers and dynamic network biomarkers (DNBs) represent new types of biomarkers with protein–protein or gene–gene interactions that can be monitored and evaluated at different stages and time-points during development of disease. Clinical bioinformatics as a new way to combine clinical measurements and signs with human tissue-generated bioinformatics is crucial to translate biomarkers into clinical application, validate the disease specificity, and understand the role of biomarkers in clinical settings. In this article, the recent advances and developments on network biomarkers and DNBs are comprehensively reviewed. How network biomarkers help a better understanding of molecular mechanism of diseases, the advantages and constraints of network biomarkers for clinical application, clinical bioinformatics as a bridge to the development of diseases-specific, stage-specific, severity-specific and therapy predictive biomarkers, and the potentials of network biomarkers are also discussed.

Edge biomarkers for classification and prediction of phenotypes.

In general, a disease manifests not from malfunction of individual molecules but from failure of the relevant system or network, which can be considered as a set of interactions or edges among molecules. Thus, instead of individual molecules, networks or edges are stable forms to reliably characterize complex diseases. This paper reviews both traditional node biomarkers and edge biomarkers, which have been newly proposed. These biomarkers are classified in terms of their contained information. In particular, we show that edge and network biomarkers provide novel ways of stably and reliably diagnosing the disease state of a sample. First, we categorize the biomarkers based on the information used in the learning and prediction steps. We then briefly introduce conventional node biomarkers, or molecular biomarkers without network information, and their computational approaches. The main focus of this paper is edge and network biomarkers, which exploit network information to improve the accuracy of diagnosis and prognosis. Moreover, by extracting both network and dynamic information from the data, we can develop dynamical network and edge biomarkers. These biomarkers not only diagnose the immediate pre-disease state but also detect the critical molecules or networks by which the biological system progresses from the healthy to the disease state. The identified critical molecules can be used as drug targets, and the critical state indicates the critical point of disease control. The paper also discusses representative biomarker-based methods.

Understanding migraine using dynamic network biomarkers.

Mathematical modeling approaches are becoming ever more established in clinical neuroscience. They provide insight that is key to understanding complex interactions of network phenomena, in general, and interactions within the migraine-generator network, in particular. In this study, two recent modeling studies on migraine are set in the context of premonitory symptoms that are easy to confuse for trigger factors. This causality confusion is explained, if migraine attacks are initiated by a transition caused by a tipping point. We need to characterize the involved neuronal and autonomic subnetworks and their connections during all parts of the migraine cycle if we are ever to understand migraine. We predict that mathematical models have the potential to dismantle large and correlated fluctuations in such subnetworks as a dynamic network biomarker of migraine.

Network biomarkers, interaction networks and dynamical network biomarkers in respiratory diseases.

Identification and validation of interaction networks and network biomarkers have become more critical and important in the development of disease-specific biomarkers, which are functionally changed during disease development, progression or treatment. The present review headlined the definition, significance, research and potential application for network biomarkers, interaction networks and dynamical network biomarkers (DNB). Disease-specific interaction networks, network biomarkers, or DNB have great significance in the understanding of molecular pathogenesis, risk assessment, disease classification and monitoring, or evaluations of therapeutic responses and toxicities. Protein-based DNB will provide more information to define the differences between the normal and pre-disease stages, which might point to early diagnosis for patients. Clinical bioinformatics should be a key approach to the identification and validation of disease-specific biomarkers.

Next-generation Bioinformatics: connecting bases to genes, networks and disease

In this issue, we present a collection of papers inspired by ISCB-Asia/SCCG 2012, an international conference on bioinformatics co-organized by the International Society of Computational Biology and BGI, known for their Sequencing Center near the conference site in Shenzhen, China. The issue begins at the whiteboard fastidiously counting bits, gradually moves into the more abstract world of inferring various kinds of gene networks and ends near the clinic reviewing methods to detect diabetes biomarkers and cancer driver mutations. In the first paper, Shrestha et al. give the reader a look ‘under-the-hood’ at how to efficiently construct suffix arrays, a data structure forming the basis for most methods used in the initial processing of high-throughput sequencing data. In the second paper, Gromiha & Ou review databases, online resources and sequence analysis techniques to characterize membrane proteins primarily from their amino acid sequence. In the third paper, Vreven et al. compare methods to predict protein–protein complexes from sequence. The next three papers focus on the inference of various kinds of networks. B. Chen et al. review methods for inferring protein–protein interaction networks from a collection of (possibly error-prone) protein–protein interaction pairs. Maetschke et al. show a little teaching can go a long way in their comparison of supervised versus unsupervised inference methods for gene regulatory networks. Kim et al. provide a comprehensive review of methods for inferring dynamic networks from time course data. Both B. Chen et al. and Kim et al. discuss the decomposition of interactions in spatial (subcellular localization) and temporal dimensions. The last two papers focus on medical applications. Li et al. review the dynamical network biomarkers method to identify genes marking pre-disease to disease transition from time course expression data, applying the method on animal models of type 2 diabetes as a test case. Finally, Zhang et al. bring us back to the genome by reviewing methods to distinguish driver mutations from passenger mutations in cancer. Despite the broad range of topics covered, several issues are encountered in multiple papers. Among the common issues are low concordance between different prediction methods, high variance in performance across samples and the difficulties in constructing realistic and informative performance benchmarks. Another common thread is the need to integrate highly diverse sources of information to produce biologically relevant results. One clear conclusion is that we have a long road ahead of us before our discipline fully catches up to the potential insights, which high-throughput sequencing promises. Even simply constructing an efficient data structure to hold sequence data is nontrivial, predicting a single interaction pair challenging, and automatically inferring genome-scale gene networks is currently infeasible. However, this issue also gives us a glimpse of what is waiting for us at the end of that road—improved health for mankind.

Deciphering early development of complex diseases by progressive module network

There is no effective cure nowadays for many complex diseases, and thus it is crucial to detect and further treat diseases in earlier stages. Generally, the development and progression of complex diseases include three stages: normal stage, pre-disease stage, and disease stage. For diagnosis and treatment, it is necessary to reveal dynamical organizations of molecular modules during the early development of the disease from the pre-disease stage to the disease stage. Thus, we develop a new framework, i.e. we identify the modules presenting at the pre-disease stage (pre-disease module) based on dynamical network biomarkers (DNBs), detect the modules observed at the advanced stage (disease-responsive module) by cross-tissue gene expression analysis, and finally find the modules related to early development (progressive module) by progressive module network (PMN). As an application example, we used this new method to analyze the gene expression data for NOD mouse model of Type 1 diabetes mellitus (T1DM). After the comprehensive comparison with the previously reported milestone molecules, we found by PMN: (1) the critical transition point was identified and confirmed by the tissue-specific modules or DNBs relevant to the pre-disease stage, which is considered as an earlier event during disease development and progression; (2) several key tissues-common modules related to the disease stage were significantly enriched on known T1DM associated genes with the rewired association networks, which are marks of later events during T1DM development and progression; (3) the tissue-specific modules associated with early development revealed several common essential progressive genes, and a few of pathways representing the effect of environmental factors during the early T1DM development. Totally, we developed a new method to detect the critical stage and the key modules during the disease occurrence and progression, and show that the pre-disease modules can serve as warning signals for the pre-disease state (e.g. T1DM early diagnosis) whereas the progressive modules can be used as the therapy targets for the disease state (e.g. advanced T1DM), which were also validated by experimental data.

Identifying critical transitions of complex diseases based on a single sample

Unlike traditional diagnosis of an existing disease state, detecting the pre-disease state just before the serious deterioration of a disease is a challenging task, because the state of the system may show little apparent change or symptoms before this critical transition during disease progression. By exploring the rich interaction information provided by high-throughput data, the dynamical network biomarker (DNB) can identify the pre-disease state, but this requires multiple samples to reach a correct diagnosis for one individual, thereby restricting its clinical application. In this article, we have developed a novel computational approach based on the DNB theory and differential distributions between the expressions of DNB and non-DNB molecules, which can detect the pre-disease state reliably even from a single sample taken from one individual, by compensating insufficient samples with existing datasets from population studies. Our approach has been validated by the successful identification of pre-disease samples from subjects or individuals before the emergence of disease symptoms for acute lung injury, influenza and breast cancer.

Prediction and early diagnosis of complex diseases by edge-network

In this article, we develop a novel edge-based network i.e. edge-network, to detect early signals of diseases by identifying the corresponding edge-biomarkers with their dynamical network biomarker score from dynamical network biomarkers. Specifically, we derive an edge-network based on the second-order statistics representation of gene expression profiles, which is able to accurately represent the stochastic dynamics of the original biological system (with Gaussian distribution assumption) by combining with the traditional node-network, which is based only on the first-order statistics representation of the noisy data. In other words, we show that the stochastic network of a biological system can be described by the integration of its node-network and its edge-network in an accurate manner. By applying edge-network analysis to gene expressions of healthy adults within live influenza experiment sampling at time points before the appearance of infection symptoms, we identified the edge-biomarkers (80 edges with 22 densely connected genes) discovered in edge-networks corresponding to symptomatic adults, which were used to predict the subsequent outcomes of influenza infection. In particular, we not only correctly predict the final infection outcome of each individual at an early time point before his/her clinic symptom but also reveal the key molecules during the disease progression. The prediction accuracy achieves ~90% under the leave-one-out cross-validation. Furthermore, we demonstrate the superiority of our method on disease classification and predication by comparing with the conventional node-biomarkers. Our edge-network analysis not only opens a new way to understand pathogenesis at a network level due to the new representation for a stochastic network, but also provides a powerful tool to make the early diagnosis of diseases. lnchen@sibs.ac.cn Supplementary data are available at Bioinformatics online.